Yarrow closes VYNE merger with $200M financing, doses first patients in thyroid drug trial
What's the deal? Yarrow BioscienceDealroom has a profile for this one. Try Dealroom → has completed its merger with VYNE Therapeutics and closed private financings totaling roughly $200 million. The combined company will trade on the Nasdaq Capital Market under the ticker "YARW" starting July 28, 2026.
What's the endgame? Yarrow, a clinical-stage biotech based in New Haven, Connecticut, is developing therapies for autoimmune thyroid diseases. Its lead candidate, YB-101, is a potential first-in-class anti-TSHR monoclonal antibody targeting both Graves' disease (GD) and thyroid eye disease (TED).
The drug blocks the thyroid stimulating hormone receptor (TSHR), the common target of autoantibodies in both the thyroid and the eye. That single mechanism aims to address both diseases with one subcutaneous treatment, with potential for infrequent dosing.
Why now? Yarrow has initiated dosing in a Phase 2a/2b trial evaluating YB-101 in patients with GD, with or without concurrent TED. The molecule has received Fast Track Designation from the US Food and Drug AdministrationDealroom has a profile for this one. Try Dealroom →, and Phase 2a data are expected in the second half of 2027.
Chief executive officer Rebecca V. Frey said current treatments "are limited, and many carry serious toxicities or fail to directly address disease-driving TSHR signaling." She added that the company has "cash runway into 2028."
What's the context? Yarrow's licensing partner, Changchun GeneScience Pharmaceutical (GenSci), is developing YB-101, also known as GenSci-098, in China. In the single ascending dose portion of a Phase 1 TED trial, the drug showed a rapid, dose-dependent proof-of-mechanism and evidence of clinical responses, with no clinically meaningful safety differences versus placebo.
Those data supported the start of the trial's multiple ascending dose (MAD) portion in China and Yarrow's Phase 2a/2b GD trial. MAD data are anticipated in the second half of 2027 and will inform global development plans for TED.
The signal: The deal is a reverse-merger route to public markets for a clinical-stage biotech, pairing a Nasdaq listing with $200 million in fresh capital. It positions Yarrow to chase two large autoimmune thyroid markets with a single candidate — a bet that hinges on clinical catalysts arriving in 2027.
Read more: Business Wire
